Answers are grounded in this paper and cite their sources.
We describe the discovery of several pyrrolopyrazines as potent and selective Syk inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies. Ultimately, our mouse model revealed unexpected toxicity that precluded us from further advancing this series.
No takes yet. Share an insight, caveat, or question.
Padilla et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: